H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Actinium Pharmaceuticals to $50 from $53 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATNM: